leisure time -WSS

leisure time

author：comprehensive 2025-09-30 20:06:16 - browse：9

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Juul spent big to court Black leaders to promote its e

hotspot

leisure time

WSS

Woodcock on FDA’s accelerated approval and her next chapter

After half a century, Israel moves to evict squatter from his cave home on the beach

The debate over Covid

The real point of Kenneth Smith’s execution by nitrogen gas

France's anti

Companies helping big Covid

hotspot

leisure time

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

ARCH Venture Partners is raising $3 billion for a life sciences fund

New air purifier tech could be key to improving indoor air quality

Commercial surrogacy can be ethical, despite pope’s claims

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Do digital therapeutics have a future in medicine?

New air purifier tech could be key to improving indoor air quality

Do digital therapeutics have a future in medicine?

Anesthesiologist group: stop taking Ozempic before surgery

EU fines Illumina $475 million over Grail acquisition

hotspot

FDA drug safety: Singulair case shows systemic surveillance flaws

The debate over Covid

A $475,000 price tag for a new cancer drug: crazy or meh?

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Britney Spears to release memoir, 'The Woman In Me,' later this year

One Duchenne patient's bittersweet hope for new treatment

focus

hotspot

leisure time

knowledge